Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 10/18 03:44:20 pm
46.718 EUR   -2.44%
02:51aBAYER AG : Receives a Buy rating from JP Morgan
MD
02:10aBAYER : Belmora Seeks SCOTUS Review For The Second Time In Its Cross-Border Trademark Battle With Bayer Over FLANAX
AQ
10/15CureVac Shares Down 12%
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer Extends Clinical Development Program for Kerendia

09/20/2021 | 08:00am EDT

Bayer announced the initiation of the FIND-CKD study, a multicenter, randomized, double-blind, placebo-controlled Phase III study for an investigational new use of KERENDIA® (finerenone) in addition to guideline-directed therapy, on the progression of chronic kidney disease (CKD) in patients with nondiabetic CKD.1 The primary objective of the study is to demonstrate superiority of finerenone over placebo in delaying the progression of CKD in these patients. The primary outcome measure is the mean rate of change in kidney function over time (estimated glomerular filtration rate [eGFR] slope) from baseline to month 32. KERENDIA – a nonsteroidal mineralocorticoid receptor antagonist (MRA) – was approved in the United States on July 9, 2021, to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction and hospitalization for heart failure in adult patients with CKD associated with type 2 diabetes (T2D).6 The KERENDIA label contains a Warning and Precaution that KERENDIA can cause hyperkalemia.6 For more information, see “Important Safety Information” .


© S&P Capital IQ 2021
All news about BAYER AG
02:51aBAYER AG : Receives a Buy rating from JP Morgan
MD
02:10aBAYER : Belmora Seeks SCOTUS Review For The Second Time In Its Cross-Border Trademark Batt..
AQ
10/15CureVac Shares Down 12%
DJ
10/15BAYER AG : Gets a Buy rating from DZ Bank
MD
10/13BAYER CROPSCIENCE : to Sell Traded Seeds Business for Over $8 Million
MT
10/13BAYER AG : Bernstein maintains a Buy rating
MD
10/12VC DAILY : Is It All or Nothing for Founders?
DJ
10/11BAYER AG : Buy rating from UBS
MD
10/08Bayer blasts 'unscientific' rejection by Mexican regulator of GMO corn permit
RE
10/08BLACKROCK : Blackstone, Carlyle Reportedly Among Suitors for German-Listed Bayer's Pest Co..
MT
More news
Analyst Recommendations on BAYER AG
More recommendations
Financials
Sales 2021 42 403 M 49 235 M 49 235 M
Net income 2021 860 M 999 M 999 M
Net Debt 2021 39 369 M 45 713 M 45 713 M
P/E ratio 2021 25,6x
Yield 2021 4,26%
Capitalization 45 796 M 53 140 M 53 175 M
EV / Sales 2021 2,01x
EV / Sales 2022 1,90x
Nbr of Employees 99 439
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | MarketScreener
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 47,89 €
Average target price 61,32 €
Spread / Average Target 28,1%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG-0.56%54 575
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657